FDA Vaccine Head Sees Promise in Covid-19 Trial Diversity

Sept. 13, 2021, 5:15 PM

Record-breaking minority recruitment for Covid-19 vaccine trials may set an example for other drug manufacturers to diversify their own clinical trials, according to the top U.S. vaccine regulator.

Of those participating in studies for the vaccines by Pfizer Inc., Moderna Inc., and Johnson & Johnson, about 10% identified as Black, 25% identified as Hispanic or Latinx, and a quarter were over the age of 65.

“Those were very nicely done and may have set a new kind of standard for what we’d like to see,” Peter Marks, director of the Center for Biologics Evaluation and Research in the Food and ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.